UT Southwestern Medical Center, Dallas
University of Texas MD Anderson Cancer Center, Houston
Methodist HealthCare System of San Antonio Clinical Trials Office, Texas Transplant Institute, San Antonio

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06297226

A Study to Assess Adverse Events and Change in Disease Activity of Oral Surzetoclax Alone or in Combination With Subcutaneous and/or Oral Antimyeloma Agents in Adult Participants With Multiple Myeloma (MM)

University of Texas - Southwestern Medical Center /ID# 271914, Dallas

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT06953960

A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatamab in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Texas MD Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06988488

A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma

Research Site, Houston

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 27. avg. 2026 · NCT07681596

MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

Baylor University Medical Center, Investigational Drug Services, Department of Pharmacy, Dallas
Baylor University Medical Center, Dallas
Houston Methodist Cancer Center Infusion, Houston
in še 9

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT06152575

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments

GSK Investigational Site, Fort Worth

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 19. avg. 2026 · NCT05714839

A Trial to Learn if Linvoseltamab is Safe and Works in Adults With Relapsed or Refractory Systemic Light Chain Amyloidosis (AL Amyloidosis)

MD Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT06292780

A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma

University of Texas Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 18. avg. 2026 · NCT05651932

AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)

Research Site, Austin
Research Site, Dallas
Research Site, Houston

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 17. avg. 2026 · NCT05850234

Minimal Residual Disease Guided Maintenance Therapy With Belantamab Mafodotin and Lenalidomide After Autologous Hematopoietic Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma

MD Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 2Vabljeni zdravi prostovoljci

Starost 18 in več · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT05091372

Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

Research Site, Dallas
Research Site, Houston

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 14. avg. 2026 · NCT07764978

A Study to Learn About the Effects of Cemsidomide in Combination With Elranatamab in Relapsed/Refractory Multiple Myeloma Subjects

Baylor University Medical Center, Dallas
Houston Methodist Hospital, Houston

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 12. avg. 2026 · NCT07280013

Phase I/II Open Label Study of Belumosudil Mesylate Alone, and in Combination With Dexamethasone, in Patients With Relapsed/Refractory Multiple Myeloma

M D Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT06105554

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

MD Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 2

Starost 18–75 · Vsi spoli · Posodobljeno 10. avg. 2026 · NCT06207799

Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

M D Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 1/2

Starost 12–80 · Vsi spoli · Posodobljeno 7. avg. 2026 · NCT05092451

A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

START San Antonio, San Antonio

Vključevanje udeležencevFaza 2

Starost 18 in več · Vsi spoli · Posodobljeno 6. avg. 2026 · NCT07284758

A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-specific Antibodies Intravenously (IV)/Subcutaneously (SC) Alone or in Combinations

University of Texas - Southwestern Medical Center /ID# 274360, Dallas

Vključevanje udeležencevFaza 1/2

Starost 18 in več · Vsi spoli · Posodobljeno 21. jul. 2026 · NCT06892522

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

University of Texas MD Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 16. jul. 2026 · NCT06121843

A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma

Texas Oncology - Central/South Texas /ID# 268563, Austin
Texas Oncology - Dallas - Worth Street /ID# 280064, Dallas
Oncology Consultants /ID# 268323, Houston
in še 1

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT05650632

A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

University of Texas Southwestern, Dallas

Vključevanje udeležencevFaza 1

Starost 18 in več · Vsi spoli · Posodobljeno 8. jul. 2026 · NCT05137054

Elranatamab Post Trial Access Study for Participants With Multiple Myeloma (MM)

St. David's South Austin Medical Center, Austin

Vključevanje udeležencevFaza 4

Starost 18 in več · Vsi spoli · Posodobljeno 1. jul. 2026 · NCT06057402

Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

MD Anderson in The Woodlands, Conroe
Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
Ben Taub General Hospital, Houston
in še 6

Vključevanje udeležencevFaza 3

Vse starosti · Vsi spoli · Posodobljeno 10. jun. 2026 · NCT05561387

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

M D Anderson Cancer Center, Houston

Vključevanje udeležencevFaza 2

Starost 18–72 · Vsi spoli · Posodobljeno 8. jun. 2026 · NCT05776979

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Houston Methodist Hospital, Houston

Vključevanje udeležencevFaza 3

Starost 18 in več · Vsi spoli · Posodobljeno 4. jun. 2026 · NCT05243797

Vir: ClinicalTrials.gov, podatki pridobljeni 4. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.